Form 4: Oric Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares
SEC Form 4 Filing
Oric Pharmaceuticals' CEO, Jacob Chacko, sold 40,000 shares of common stock on March 6, 2024, at a weighted average price of $16.2095.
Summary
- On March 6, 2024, Jacob Chacko, the President and CEO of Oric Pharmaceuticals, sold 40,000 shares of the company's common stock.
- The sale was executed at a weighted average price of $16.2095 per share.
- The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 28, 2022.
- Following the reported transaction, Chacko directly owns 728,544 shares of Oric Pharmaceuticals' common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider stock sale. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company executives and directors, allowing investors to monitor potential alignment of interests and assess confidence levels.
Stakeholder Impact
- The stock sale by the CEO could be perceived neutrally or slightly negatively by shareholders, depending on their interpretation of the reasons behind the sale.
Key Dates
| Date | Description |
|---|---|
| December 28, 2022 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| March 6, 2024 | Date of the stock sale transaction |
| March 8, 2024 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.